Table 4. Survival and Pathways.
Pathway Name or Other Variable | Coefficient | P-value |
Stage 2 | 1.00 | <0.0001 |
Stage 3 | 1.56 | <0.0001 |
Cell Cycle (+) | 0.37 | <0.0001 |
Notch | 0.015 | 0.91 |
Hedgehog | 0.14 | 0.09 |
B-cell | −0.26 | 0.037 |
Hypoxia | −0.20 | 0.11 |
EGFR | −0.21 | 0.014 |
IL-suppressive | 0.19 | 0.20 |
Cell Cycle (−) | −0.14 | 0.12 |
Age | 0.035 | <0.0001 |
Stage 2 : Notch | −0.056 | 0.78 |
Stage 3 : Notch | 0.39 | 0.043 |
Stage 2 : B-cell | −0.39 | 0.11 |
Stage 3 : B-cell | 0.21 | 0.36 |
Stage 2 : Hypoxia | 0.26 | 0.17 |
Stage 3 : Hypoxia | 0.42 | 0.063 |
Stage 2 : IL-suppressive | 0.70 | 0.0045 |
Stage 3 : IL-suppressive | 0.11 | 0.61 |
The cell cycle stimulatory (CC+) pathway gives additional prognostic information beyond standard clinical covariates such as stage and age, where patients with greater expression levels of the CC+ pathway have an increased hazard compared to those with relative underexpression. The B-cell and EGFR pathways also give additional information where patients with relative overexpression of either of these pathways to better although the relationship with the B-cell pathway only exists in stage 1 patients. In addition, stage 3 patients with relative overexpression of the Notch or the response to hypoxia pathway do worse while stage 2 patients with relative overexpression of pathway representing activity of immunosuppressive interleukins did poorer. Variables not listed were dropped during model selection.